Arcus Biosciences, Inc. (RCUS) Institutional Ownership

Ownership Summary

Arcus Biosciences, Inc. (NYSE:RCUS) showed up in the 13F filings of 208 institutional investors as of March 2026.

• Their combined ownership stood at 95.0% of outstanding shares in March 2026, down from 113.2% in December 2025.
• Their total shares held in RCUS increased 10.02% quarter over quarter, and separately, investors owning Arcus Biosciences increased 10.05% from a year ago.
• Of these 208 holders, 119 added to their stakes in Arcus Biosciences, 57 trimmed positions, and 32 made no changes.
• Altogether, these fund groups held 119.12Mn shares in RCUS by March 2026, up by 10.84Mn shares quarter on quarter, and up 13.85Mn shares year over year.
• Gilead Sciences, Inc. holds the largest position in RCUS at 31.42Mn shares as of March 31, 2026, or 25.06% of shares outstanding.
• Leading buyers of Arcus Biosciences shares for the quarter ending March 2026 were VANGUARD PORTFOLIO MANAGEMENT LLC (4.27Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.86Mn), CITADEL ADVISORS LLC (1.23Mn), Parkman Healthcare Partners LLC (1.21Mn), Logos Global Management LP (1.2Mn).
• The largest sellers of Arcus Biosciences for the quarter ending March 2026 were Point72 Asset Management, L.P. (3.15Mn), Goldman Sachs Group Inc (1.34Mn), Barclays Plc (1.04Mn), Caption Management, LLC (751.66K), JACOBS LEVY EQUITY MANAGEMENT, INC (499.64K).
• Arcus Biosciences's 10 largest shareholders as of March 2026 include Gilead Sciences, Inc. (31.42Mn), BlackRock, Inc. (15.23Mn), WELLINGTON MANAGEMENT GROUP LLP (6.09Mn), State Street Corp (5.41Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (5.03Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (4.27Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.86Mn), Woodline Partners LP (3.78Mn), MARSHALL WACE, LLP (3.76Mn), Siren, L.L.C. (3.01Mn) per Business Quant data.